Literature DB >> 1698727

Expression and production of tenascin in benign and malignant lesions of melanocyte lineage.

P G Natali1, M R Nicotra, A Bartolazzi, M Mottolese, N Coscia, A Bigotti, L Zardi.   

Abstract

The distribution of the extracellular matrix (ECM) glyco-protein tenascin (TN) has been evaluated immunohistochemically in benign and malignant lesions of the melanocytic lineage. Results of our study show that TN is detectable in a variety of benign and malignant lesions. In primary melanomas, TN displays a heterogeneous distribution, and a higher degree of expression of this glycoprotein is seen in lesions of greater dermal invasiveness. TN expression does not correlate with that of other ECM glycoproteins such as fibronectin. In vivo and in vitro experiments have also demonstrated that melanoma cells are capable of producing and releasing TN in the extracellular milieu.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1698727     DOI: 10.1002/ijc.2910460406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  Tenascins and the importance of adhesion modulation.

Authors:  Ruth Chiquet-Ehrismann; Richard P Tucker
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-05-01       Impact factor: 10.005

2.  The human placenta: a model for tenascin expression.

Authors:  M Castellucci; I Classen-Linke; J Mühlhauser; P Kaufmann; L Zardi; R Chiquet-Ehrismann
Journal:  Histochemistry       Date:  1991

3.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

4.  Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

Authors:  J A Reed; N S McNutt; V G Prieto; A P Albino
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 5.  Tenascin-C Signaling in melanoma.

Authors:  Hanshuang Shao; John M Kirkwood; Alan Wells
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

6.  Tenascin immunoreactivity in normal and pathological bone marrow.

Authors:  Y Soini; D Kamel; M Apaja-Sarkkinen; I Virtanen; V P Lehto
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

7.  Tenascin in salivary gland tumours.

Authors:  Y Soini; P Pääkkö; I Virtanen; V P Lehto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 8.  Tenascin C in metastasis: A view from the invasive front.

Authors:  Camille M Lowy; Thordur Oskarsson
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

9.  Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions.

Authors:  P G Natali; M R Nicotra; F Di Filippo; A Bigotti
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

10.  Immunohistochemical expression of tenascin in normal stomach tissue, gastric carcinomas and gastric carcinoma in lymph nodes.

Authors:  Y Ikeda; M Mori; K Kajiyama; Y Haraguchi; O Sasaki; K Sugimachi
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.